Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21531165 | 0.83 | MAPT (0.40) | KMT2AFOLH1MAPTKDM4EALDH1A1 | |
| SCHEMBL20399861 | 0.83 | KMT2A (0.41) | KMT2ASRD5A2FOLH1MAPTKDM4E | |
| SCHEMBL21531212 | 0.79 | MAPT (0.52) | KMT2AFOLH1MAPTKDM4EALDH1A1 | |
| SCHEMBL21531127 | 0.77 | KMT2A (0.60) | KMT2AFOLH1MAPTKDM4EALDH1A1 | |
| SCHEMBL23705089 | 0.74 | MAPT (0.57) | KMT2AFOLH1MAPTKDM4EALDH1A1 | |
| SCHEMBL20402644 | 0.74 | MAPT (0.57) | KMT2AFOLH1MAPTKDM4EALDH1A1 | |
| SCHEMBL23705002 | 0.73 | MAPT (0.49) | KMT2AFOLH1MAPTKDM4EALDH1A1 | |
| SCHEMBL4427988 | 0.72 | MAPT (0.57) | KMT2AFOLH1MAPTKDM4EALDH1A1 | |
| SCHEMBL31481345 | 0.72 | MAPT (0.57) | KMT2AFOLH1MAPTKDM4EALDH1A1 | |
| SCHEMBL21531203 | 0.72 | MAPT (0.55) | KMT2AFOLH1MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-12-09 | — | — | US | disclosed |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | KMT2A 3572/4885SRD5A2 4300/4885FOLH1 1157/4885 |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | KMT2A 3699/4885SRD5A2 4417/4885FOLH1 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.